Company Gets Two Grants to Advance its Drug Discovery Pipeline

LEXINGTON, KY. and NEW YORK, NY. (June 14, 2019) – Gismo Therapeutics Inc. has been awarded two grants to continue its development of therapies to treat Alzheimer’s Disease. A $952,480 SBIR grant award represents a second year of a $1.88 million grant, entitled “Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer’s Therapeutics”, awarded by the National Institute on Aging (NIA), National Institutes of Health (NIH). Gismo Therapeutics also received a $500,000 Kentucky SBIR Matching Funds grant from the Kentucky’s Cabinet for Economic Development.

The funds will allow the company to advance its pipeline of therapeutic candidates directed against neurodegenerative diseases. Gismo Therapeutics will leverage its expertise in small-molecule compounds that target glycosaminoglycans (GISMOs). Glycosaminoglycans have been identified as key molecules in the disease process, by promoting the internalization of amyloid peptides into nerve cells and spreading throughout the nervous system, advancing the neurodegeneration and disease process. By intervening with its purpose-designed GISMO compounds, the company aims to mitigate this disease progression.

Under the NIA grant, the company is collaborating with the team of Prof. Michael P. Murphy, Ph.D., Department of Molecular and Cellular Biochemistry, Saunders-Brown Center for Aging, University of Kentucky, Lexington, Ky.

“We are pleased to have been awarded these two grants to identify new therapeutics for the treatment of Alzheimer’s disease,” said Paul Gregor, Ph.D., company’s founder and CEO. “These funds will allow the company to advance its program from the drug discovery phase to preclinical testing, with the aim of initiating IND-enabling studies.”

About Gismo Therapeutics Inc.:

Gismo Therapeutics Inc. is a biotech start-up company targeting fundamental biochemical processes that are at the root cause of amyloid neurodegenerative diseases pathogenesis. The company is developing its pioneering technology, GISMO, which is associated with a new hypothesis of the etiology of major neurodegenerative diseases. Gismo Therapeutics Inc. is developing first-in-class, disease modifying oral therapeutics for the treatment of Alzheimer’s and Parkinson’s Disease. Gismo Therapeutics Inc. was incorporated in Delaware and has offices in Lexington, Kentucky and Queens, New York. The company is privately held and supported by grants from the NIH and the Kentucky Cabinet for Economic Development, and by private funding. The company was founded by Paul Gregor, Ph.D., CEO, a graduate of the Weizmann Institute of Science (Rehovot, Israel). Its Scientific Advisory Board includes Dennis Choi, M.D., Ph.D., an award-winning neurologist, Chair of Department of Neurology and Director of the Neuroscience Institute, Stony Brook University, New York, and Prof. Bruce F. O’Hara, Ph.D., Department of Biology, University of Kentucky, Lexington, KY.

For more information about Gismo Therapeutics Inc., visit the company’s website, www.gismotherapeutics.com.

Contact:
Dr. Paul Gregor
Tel: (347) 233-2037
e-mail: informa@gismotherapeutics.com